International Journal of Bipolar Disorders最新文献

{"title":"Creativity and transition to bipolar disorder: a prospective analysis from the early-bipolife study.","authors":"Elisabeth Michaelis, Michael Bauer, Andreas Bechdolf, Felix Bermpohl, Christina Berndt, Kyra L Bröckel-Bundt, Eva Burkhardt, Christoph U Correll, Udo Dannlowski, Irina Falkenberg, Andreas J Fallgatter, Paolo Fusar-Poli, Sarina Hadji, Andreas Jansen, Georg Juckel, Tilo Kircher, Sarah Kittel-Schneider, Seza Krüger-Özgürdal, Martin Lambert, Karolina Leopold, Birgit Maicher, Silke Matura, Eva Mennigen, Pavol Mikolas, Andreas Reif, Philipp Ritter, Cathrin Sauer, Thomas Stamm, Julia Martini, Andrea Pfennig","doi":"10.1186/s40345-025-00406-6","DOIUrl":"10.1186/s40345-025-00406-6","url":null,"abstract":"<p><strong>Background: </strong>Bipolar disorders (BD) are severe mental illnesses with recurrent depressive and (hypo-)manic episodes and a chronic course. While anecdotal and cross-sectional studies suggest a link between BD and creativity, longitudinal evidence is limited. This study investigates the role of creativity in individuals with varying risk for developing BD, using data from the multicenter, prospective Early-BipoLife study. N = 1,255 individuals aged 15-35 years were assessed and followed for over two years. Of these, N = 1,105 were included in the analyses; 150 were excluded due to missing creativity questionnaires. Creativity was measured with the Barron-Welsh Art Scale (BWAS) and the Creative Achievement Questionnaire (CAQ); BD risk was assessed with the EPIbipolar. Analyses included comparisons of mean creativity scores across BD risk groups and logistic regressions testing prospective associations between continuous creativity scores and transition to manifest BD. To enhance clinical applicability, group comparisons and odds ratios (ORs) were also calculated, providing estimates of relative risk across subgroups defined by BD risk status and creativity level.</p><p><strong>Results: </strong>At baseline (BL), participants at high BD risk scored significantly higher on the CAQ than those at low risk, while no differences were observed for BWAS scores. During FU, 25 of 1,105 individuals transitioned to manifest BD. Logistic regression analyses did not reveal significant associations between creativity and transitions. However, group comparisons indicated elevated transition likelihood in individuals with high BD risk, with the highest ORs in those combining high BD risk and high creativity (BWAS: OR = 7.05, 95% CI: 1.94-25.56; CAQ: OR = 5.57, 95% CI: 1.88-16.54) compared to low-risk individuals with low creativity.</p><p><strong>Conclusions: </strong>High BD risk was associated with higher CAQ scores at BL, suggesting heightened creativity may precede transition. Prospective analyses over two years did not confirm this association, likely due to the small number of transitions. Nonetheless, cross-sectional differences and group comparisons suggest that individuals with both high BD risk and high creativity, particularly real-world accomplishments captured by the CAQ, may show an increased likelihood of transition. These preliminary findings warrant replication in larger, longer-term studies. Importantly, creativity should not be pathologized but considered both as a resource and as a potential modifier of risk trajectories.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":" ","pages":"5"},"PeriodicalIF":3.5,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12860774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The breakthrough discoveries for thriving with bipolar disorder (BD²) integrated network longitudinal cohort protocol.","authors":"Emily G Baxi, Megan Shanahan, Daniel L Pham, Veronica C Beck, Kelsey M Barcomb, Eric J Nestler, Mark A Frye, Cara M Altimus, Katherine E Burdick","doi":"10.1186/s40345-025-00399-2","DOIUrl":"10.1186/s40345-025-00399-2","url":null,"abstract":"<p><p>Bipolar Disorder (BD) is a highly complex and heterogeneous disorder. As such, accurate diagnosis is often delayed, and effective treatment options are limited. The Integrated Network, a program of Breakthrough Discoveries for thriving with Bipolar Disorder (BD²), was designed as a platform for longitudinal deep phenotyping of a diverse group of people with bipolar disorder to define disease trajectories and to gain insight into the biological drivers of the illness. Biosamples, including whole blood, serum, plasma, and peripheral blood mononuclear cells (PBMCs), will be collected longitudinally and will also be made available. The Integrated Network is designed to be the largest and most comprehensive prospective longitudinal study conducted in bipolar disorder, allowing for the development of precision-based treatment strategies that optimize quality of life for people living with bipolar disorder.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"13 1","pages":"36"},"PeriodicalIF":3.5,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12722624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing the prediction of factors associated with bipolar disorder risk: utilizing early recognition tools and polygenic risk scores.","authors":"Silvia Biere, Silke Matura, Kristiyana Petrova, Fabian Streit, Andreas G Chiocchetti, Kira F Ahrens, Charlotte Schenk, Michael M Plichta, Raffael Kalisch, Michèle Wessa, Viola Oertel, Andrea Pfennig, Michael Bauer, Philipp Ritter, Thomas G Schulze, Christoph U Correll, Andreas Bechdolf, Klaus Lieb, Oliver Tüscher, Sarah Kittel-Schneider, Andreas Reif, Thorsten M Kranz","doi":"10.1186/s40345-025-00404-8","DOIUrl":"10.1186/s40345-025-00404-8","url":null,"abstract":"<p><p>Bipolar disorder (BD) is a highly heritable mental illness that affects ∼ 1-2% of the world's population and has complex genetic and environmental underpinnings. Early detection is critical to improving treatment outcomes, but current strategies have limited predictive power. Early detection tools such as the Early Phase Inventory for Bipolar Disorder (EPIbipolar) and the Bipolar At-Risk (BARS) criteria assess phenotypic risk factors, including family history (FH) and subthreshold mood problems. Polygenic risk scores (PRS) are a quantitative metric of genetic susceptibility. This study examined the associations between BD-PRS and screening tools in order to assess their combined potential to identify individuals at risk of BD with improved predictive accuracy. The analysis included 1068 participants, including 199 at-risk young adults aged 15 to 35 years and 869 healthy controls aged 18 to 50 years. All of them had no prior psychiatric disorders. Inclusion criteria for the at-risk group comprised a positive FH (1st or 2nd degree) for BD, major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), or the presence of specific BD risk factors (e.g., subthreshold hypomanic symptoms, mood swings, or sleep disturbances). Participants who had a confirmed BD, schizophrenia, schizoaffective disorder diagnosis, or other psychiatric conditions that could explain the symptomatology, were excluded. Diagnostic assessments that were utilized validated early detection instruments, including EPIbipolar, Bipolar Prodrome Interview and Symptom Scale-Prospective (BPSS-FP), and BARS criteria. Binary logistic regression models were employed to assess associations between BD-PRS and phenotypic risk markers, with adjustments for population stratification. Results revealed significant associations between BD-PRS and BARS criteria risk groups and EPIbipolar \"at risk\" criteria compared to controls. Significant associations were also identified for subscales including FH for BD, MDD, or schizophrenia, sleep and circadian rhythm disturbances, depressive characteristics, functional impairment, and episodic course. However, no significant associations were observed between BD-PRS and BPSS-FP, which highlights variability in the sensitivity of different early detection instruments. Our findings emphasize the potential of combining genetic susceptibility measures with phenotypic risk markers to enhance early detection strategies for BD. Further research is needed to optimize predictive models and evaluate the clinical utility of PRS in early intervention frameworks.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":" ","pages":"2"},"PeriodicalIF":3.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12804565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behavioural therapy for inter-episode bipolar symptoms: a multiple baseline case series evaluation.","authors":"Kim Wright, Sandra Bucci, Iona Cairns, Barnaby D Dunn, Steven Jones, Heather O'Mahen, Daniel Scott, Rod S Taylor","doi":"10.1186/s40345-025-00402-w","DOIUrl":"10.1186/s40345-025-00402-w","url":null,"abstract":"<p><strong>Background: </strong>Between major affective episodes some people with bipolar disorder experience persistent low mood or mood instability. Here we report an initial evaluation of the STABILISE programme (ISRCTN19416314; registration date 01.02.23), an adaptation of individual behavioural therapy that includes concepts and techniques addressing emotion regulation designed to support people experiencing these inter-episode symptoms. This study aimed to evaluate the safety, feasibility and acceptability of the intervention and to explore whether the pattern of clinical change had potential for the intervention to be of benefit. Twelve individuals with inter-episode bipolar symptoms received the STABILISE therapy in a randomised, multiple baseline case series. Participants were randomly assigned to wait 3, 4 or 5 weeks before commencing treatment, which comprised up to 22 sessions up to 7 months. Measures of symptoms, mood lability, recovery and quality of life were completed at intake, pre-therapy, and post therapy. Participants completed weekly measures of affective symptoms over the baseline and therapy periods, and for three weeks after.</p><p><strong>Results: </strong>All 12 participants completed the therapy programme and reported high levels of satisfaction overall. No adverse events were judged to be therapy related. There was one instance of reliable deterioration on one outcome measure. Across all parameters of clinical change 9 of the 12 participants showed an overall pattern of improvement and none showed a pattern of deterioration overall.</p><p><strong>Conclusions: </strong>This study provides preliminary support for the feasibility, acceptability, safety, and clinical potential of the STABILISE therapy. Further investigation of these aspects in a larger sample and within a randomised controlled trial design is required.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":" ","pages":"3"},"PeriodicalIF":3.5,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic use in bipolar disorder: clinical and genomic correlates- a Mayo clinic bipolar disorder biobank study.","authors":"Balwinder Singh, Ada Man-Choi Ho, Brandon J Coombes, Francisco Romo-Nava, David J Bond, Marin Veldic, Richard S Pendegraft, Anthony Batzler, Alfredo B Cuellar-Barboza, Manuel Gardea-Reséndez, Miguel L Prieto, Aysegul Ozerdem, Susan L McElroy, Joanna M Biernacka, Mark A Frye","doi":"10.1186/s40345-025-00405-7","DOIUrl":"10.1186/s40345-025-00405-7","url":null,"abstract":"<p><strong>Background: </strong>Responsiveness to mood-stabilizing pharmacotherapy varies in bipolar disorder (BD). We investigated clinical correlates of second-generation antipsychotic (SGA) treatment response and conducted the first genome-wide association study (GWAS), including exploratory polygenic scores (PGS), of SGA pharmacogenomic treatment response in BD.</p><p><strong>Methods: </strong>Treatment response was quantified using the Alda scale, and GWAS was performed using Alda-A score, controlling for sex, genotyping batch, and the genomic principal components.</p><p><strong>Results: </strong>The cohort included 2,159 adults with BD (1,416 BD-I, 691 BD-II, 51 schizoaffective BD), mean age 41.8 years, 62% female, 84% white, and 14% Hispanic. Nearly half (48%) were treated with SGAs. Current SGA users were younger (41.2 ± 14.7 vs. 42.5 ± 15.3 years, p = 0.040), more likely to be Hispanic (14% vs. 11%, p = 0.047), had a higher body mass index (BMI; 30.4 ± 7.6 vs. 29.5 ± 7.1 kg/m², p = 0.005). Lifetime comorbidity patterns for current SGA users include higher rates of manic psychosis (29% vs. 17%, p < 0.001) and eating disorders - Anorexia Nervosa (7% vs. 4%, p = 0.003), Bulimia Nervosa (7% vs. 4%, p = 0.003), and Binge Eating Disorder (14% vs. 11%, p = 0.030). We detected a genome-wide significant association between SGA Alda-A scores and GAS7 variants (top variant: rs202127418, β=-2.998, p = 4.96E-08). However, SGA response was not significantly associated with PGS for schizophrenia, BD, and major depression (FDR > 0.05).</p><p><strong>Conclusions: </strong>SGAs are frequently utilized as mood stabilizers in patients with BD and are associated with manic psychosis and eating disorders. GAS7 variants may predict SGA response, but larger, more diverse cohorts are needed for validation.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":" ","pages":"1"},"PeriodicalIF":4.5,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between negative symptoms and thermal pain perception in bipolar I disorder.","authors":"Lise Vrolix, Jon Haitz Legarreta, Hanne van der Heijden, Raquel van Gool, Aliza Ray, Emma Golden, Mariesa Cay, Yogesh Rathi, Joseph Gonzalez-Heydrich, Lauren J O'Donnell, Ann K Shinn, Jaymin Upadhyay","doi":"10.1186/s40345-025-00403-9","DOIUrl":"10.1186/s40345-025-00403-9","url":null,"abstract":"<p><strong>Background: </strong>There is emerging evidence that negative symptoms are a source of functional impairment for individuals with bipolar I disorder (BD). Patients with BD may also demonstrate notable changes in the perception of pain. The objective of this preliminary study was to explore potential associations between negative symptom severity and pain perception (measured with quantitative sensory testing (QST)) in BD as well as identify neurobiological correlates of these two domains.</p><p><strong>Results: </strong>In patients with BD (N = 24, 30.3 ± 9.4 years of age), the Clinical Assessment Interview for Negative Symptoms (CAINS) Total and CAINS Motivation and Pleasure (MAP) subscale scores were associated with cold pain detection thresholds (CAINS Total: ρ = -0.49, p_UNC = 0.02, p_FDR = 0.09; CAINS MAP: ρ = -0.61, p_UNC = 0.003, p_FDR = 0.047; controlled for chlorpromazine (CPZ)-equivalent dose and Montgomery-Åsberg Depression Rating Scale (MADRS) scores). Parallel findings were observed for heat pain detection thresholds (CAINS Total: Spearman's ρ = 0.55, p_UNC = 0.009, p_FDR = 0.057; CAINS MAP: ρ = 0.54, p_UNC = 0.01, p_FDR = 0.057). Associations among CAINS expression scores and any QST-based measure less robust. An advanced multi-tensor model of crossing fibers was used to analyze Diffusion Tensor Imaging (DTI) data (N = 20). Here, the fractional anisotropy (FA) of the superior longitudinal fasciculus I (SLF-I), a white matter pathway integrating sensorimotor (Brodmann areas 5 and 7), parietal, and frontal cortices was associated with negative symptom severity (CAINS Total: ρ = -0.55, p_UNC = 0.019, p_FDR = 0.09; CAINS MAP: ρ = -0.56, p_UNC = 0.016; p_FDR = 0.09). A slightly more moderate trend between the FA of SLF-I and heat pain detection thresholds (ρ = -0.48, p_UNC = 0.044; p_FDR = 0.26) and heat pain tolerances (ρ = -0.53, p_UNC = 0.022; p_FDR = 0.26) was observed.</p><p><strong>Conclusion: </strong>This preliminary study points to the relationship among negative symptom severity and the perception of pain in adults with BD. These findings suggest that thermal pain hypoalgesia in patients with BD may serve as a behavioral marker of negative symptoms, particularly in the MAP domain, potentially reflecting disruptions in sensory-affective integration. Further research with larger samples is warranted to clarify underlying neurobehavioral mechanisms.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":" ","pages":"35"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12698911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-assessment and rest-activity rhythm monitoring for effective bipolar disorder management: a longitudinal actigraphy study.","authors":"Bianca Pfaffenseller, Jakub Schneider, Taiane de Azevedo Cardoso, Mario Simjanoski, Martin Alda, Flavio Kapczinski, Eduard Bakstein","doi":"10.1186/s40345-025-00401-x","DOIUrl":"10.1186/s40345-025-00401-x","url":null,"abstract":"<p><strong>Background: </strong>Recurrent course and disruption of circadian rhythms are among the core features of bipolar disorder (BD). Thus, ongoing symptom monitoring is an essential part of good clinical management.</p><p><strong>Objective: </strong>We conducted a study to validate the English version of the ASERT (Aktibipo questionnaire), a tool for self-assessment of mood symptoms. We also analyzed the relationship of self-assessed symptoms with clinician ratings and actigraphy measures, and investigated the possibility of predicting depressive episodes using subjective and digital measures.</p><p><strong>Methods: </strong>This was a longitudinal study of twenty individuals with BD, followed for up to 11 months. The participants completed weekly mood self-assessments (ASERT) using a smartphone app and wore wrist actigraphs. During monthly appointments, the severity of their mood symptoms was rated by clinicians, and the participants completed questionnaires addressing overall functioning (FAST), and biological rhythms (BRIAN).</p><p><strong>Results: </strong>The study confirmed the validity and reliability of the ASERT as a measure of subjective mood. Additionally, we found significant associations between ASERT responses, clinical scales, and actigraphy data (ASERT_dep vs. MADRS β = 1.42, p < 0.001, ASERT_man vs. YMRS β = 0.38, p < 0.001, mixed-effect model). In our analysis, a combination of self-assessment and actigraphy data detected depression relapse with 67% sensitivity, 90% specificity, 81% balanced accuracy, and AUC of 0.80. Furthermore, we observed a strong correlation between the actigraphy-derived interdaily stability and BRIAN scores (β=-3.86, p = 0.005) overall functioning, emphasizing the significance of circadian rhythm disruptions in BD.</p><p><strong>Conclusion: </strong>This study highlights the potential of digital tools, such as digitally administered self-assessments and actigraphy, to enhance the management of BD by providing valuable insights into mood states and detecting relapse. Further research is needed to refine and optimize these tools for widespread clinical application, such as informing personalized treatment plans.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"13 1","pages":"34"},"PeriodicalIF":3.5,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12662911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145632904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight gain under antipsychotic and mood stabilizing treatment: a narrative review about mechanisms and future options.","authors":"Hilda T Seiter, Frederike T Fellendorf, Darja Popkova, Eva Z Reininghaus","doi":"10.1186/s40345-025-00397-4","DOIUrl":"10.1186/s40345-025-00397-4","url":null,"abstract":"<p><strong>Background: </strong>Pharmacological treatment for mental illness can paradoxically compromise physical health, with weight gain and related cardiovascular and metabolic diseases among its most concerning side effects. Understanding and mitigating the metabolic consequences of antipsychotic and mood stabilizing treatments is therefore crucial for improving long-term health outcomes in individuals with severe mental illness such as schizophrenia and bipolar disorder. This literature review focuses on the underlying mechanisms linking antipsychotics and mood stabilizers to weight gain in bipolar disorder. Current evidence on both pharmacologic and nonpharmacologic strategies to prevent this side effect is also addressed.</p><p><strong>Methods: </strong>A literature search was conducted from February-April 2025 using PubMed and Google Scholar. The electronic search was complemented by a manual search for additional articles in reference lists and previous reviews. Relevant reviews, cohort studies, meta-analyses and randomized controlled trials (RCTs) were reviewed.</p><p><strong>Results: </strong>Our results support that different mood stabilizers and antipsychotics contribute to weight gain through distinct biological mechanisms, including metabolic dysregulation, appetite modulation, and hormonal changes. Nonpharmacologic interventions, such as dietary modifications, physical activity, cognitive and behavioral strategies, play a crucial role in counteracting medication-induced weight gain. Pharmacologic approaches, including adjunctive medications, offer potential in mitigating weight gain, but their effectiveness and safety profiles require further evaluation.</p><p><strong>Conclusion: </strong>Customized treatment plans tailored to each patient's needs, preferences, goals and circumstances should be considered for the treatment of antipsychotic and mood stabilizer-associated weight gain.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"13 1","pages":"33"},"PeriodicalIF":3.5,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12647513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145603967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The barriers and solutions to effective management of bipolar disorder during the perinatal period: a thematic review.","authors":"Mohsen Khosravi","doi":"10.1186/s40345-025-00400-y","DOIUrl":"10.1186/s40345-025-00400-y","url":null,"abstract":"<p><strong>Background: </strong>Perinatal bipolar disorder (BD) presents unique challenges due to physiological, hormonal, and psychosocial changes during pregnancy and postpartum, increasing vulnerability to mood instability. Effective management is vital for maternal and infant health, but multiple barriers complicate care. This review aims to clarify whether obstacles arise from limited psychiatric expertise among obstetric providers, insufficient perinatal knowledge among psychiatric providers, or both.</p><p><strong>Methods: </strong>A thematic review was conducted following PRISMA guidelines, synthesizing literature (2015-2025) from major databases and clinical guidelines on barriers and solutions in perinatal BD management. Both qualitative and quantitative studies were included. Data extraction, quality assessment, and thematic analysis were performed by multiple independent reviewers.</p><p><strong>Results: </strong>Four major barriers were identified: (i) Diagnostic challenges-obstetric providers may miss or misdiagnose BD due to symptom overlap with normal perinatal changes, while psychiatric providers may lack specific perinatal expertise; (ii) Treatment issues-concerns about medication safety, particularly among obstetricians, and limited access to specialized psychiatric care, leading to increased relapse risk; (iii) Psychosocial barriers-stigma, inadequate support, and new maternal responsibilities hinder help-seeking; (iv) Poor interprofessional communication-fragmented care often results when obstetric and psychiatric providers lack coordination. These barriers adversely impact both mothers and infants, increasing relapse rates and impairing mother-infant bonding. Proposed solutions include improved diagnostic training for both provider types, integrated care models, enhanced patient education, support systems, and policy reforms. However, there remain knowledge gaps regarding long-term outcomes and optimal screening.</p><p><strong>Conclusions: </strong>Effective perinatal BD management requires multidisciplinary, individualized, and integrated care addressing both clinical and psychosocial barriers. Bridging knowledge gaps between obstetric and psychiatric providers through education, research, and policy reform is essential to improve outcomes for mothers and their families.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"13 1","pages":"32"},"PeriodicalIF":3.5,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12586828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in emotional dysregulation profile among offspring of parents with bipolar disorder: a family-based intervention pilot study.","authors":"Erica Fongaro, Florence Pupier, Marie-Christine Picot, Nathalie Franc, Marion Soler, Emilie Olié, Virginie Maurice, Diane Purper-Ouakil, Hala Kerbage","doi":"10.1186/s40345-025-00398-3","DOIUrl":"10.1186/s40345-025-00398-3","url":null,"abstract":"<p><p>Offspring of parents with bipolar disorder (OBD) are at increased risk for mood and behavioral disorders, with emotional dysregulation being an early marker. This pilot study aimed to evaluate the effect of a family-focused intervention on emotional dysregulation in OBD, hypothesizing a significant reduction in CBCL Emotional Dysregulation Profile scores over 12 months. Twenty-five OBD aged 6-16 years participated in a four-session psychoeducational program. Significant reductions were observed in CBCL emotional dysregulation scores suggesting that a brief family-focused program may reduce dysregulation and improve functioning in OBD. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov. ID NCT03299140. Registered on the 17th September, 2017.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":"13 1","pages":"31"},"PeriodicalIF":3.5,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12583260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}